Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers thermal capsulorrhaphy as a treatment of joint instability, including, but not limited to the shoulder, knee and elbow, to be not medically necessary.**

Background/Overview
Shoulder instability is a relatively common occurrence, reported in between 2% and 8% of the population. The condition may arise from a single traumatic event (i.e., subluxation or dislocation), repeated microtrauma, or constitutional ligamentous laxity, resulting in deformation and/or damage in the glenohumeral capsule and ligaments. Shoulder instability may be categorized according to the movement of the humeral head (i.e., either anterior, posterior, inferior, or multidirectional instability). Multidirectional instability most frequently consists of anterior and inferior subluxation or dislocation. Inferior movement is also classified as multidirectional.

Initial treatment of shoulder subluxation or dislocation is conservative in nature followed by range-of-motion and strengthening exercises. However, if instability persists, either activity modifications or surgical treatment may be considered. Activity modification may be appropriate for patients who can identify a single motion that aggravates instability, such as overhead throwing motions. Surgical treatment may be considered in those who are unwilling to give up specific activities (i.e., related to sports) or when instability occurs frequently or during daily activities.

Surgery consists of inspection of the shoulder joint with repair, reattachment, or tightening of the labrum, ligaments, or capsule performed either with sutures or sutures attached to absorbable tacks or anchors. While arthroscopic approaches have been investigated over the past decade, their degree of success has been controversial due to a higher rate of recurrent instability compared with open techniques, thought to be related in part to the lack of restoration of capsular tension. Recent reports of arthroscopic techniques have described various suturing techniques for tightening the capsule, which require mastery of technically difficult arthroscopic intra-articular knot-tying.
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

Thermal capsulorrhaphy has been proposed as a technically simpler arthroscopic technique for tightening the capsule and ligaments. The technique is based on the observation that the use of nonablative levels of radiofrequency thermal energy can alter the collagen in the glenohumeral ligaments and/or capsule, resulting in their shrinkage and a decrease in capsular volume, both thought to restore capsular tension. Thermal capsulorrhaphy may be used in conjunction with arthroscopic repair of torn ligaments or other structures (i.e., repair of Bankart or superior labrum anterior and posterior lesion). In addition, thermal capsulorrhaphy has been investigated as an arthroscopic treatment of glenohumeral laxity, a common injury among overhead athletes, such as baseball players, resulting in internal impingement of the posterior rotator cuff against the glenoid labrum. Internal impingement is often accompanied by posterior rotator cuff tearing and labral injury. Thermal capsulorrhaphy has also been proposed as a sole arthroscopic treatment. For example, the technique may be considered in patients with chronic shoulder pain without recognized instability, based on the theory that the pain may be related to occult or microinstability. This diagnosis may be considered when a diagnostic arthroscopy reveals only lax ligaments and is commonly seen among baseball players. Finally, thermal capsulorrhaphy may be considered in patients with congenital ligamentous laxity, such as Ehlers-Danlos or Marfan syndrome.

While thermal capsulorrhaphy was initially investigated using laser energy, the use of radiofrequency probes is now more commonly employed. Devices include Oratec® ORA-50 Monopolar RF Generator (Oratec Interventions, Menlo Park, CA) and ArthroCare® (ArthroCare, Sunnyvale, CA).

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Thermal capsulorrhaphy is a surgical procedure and, as such, is not subject to regulation by the U.S. FDA. Previously a number of electrosurgical cutting and coagulation devices were cleared for marketing by FDA through the 510(k) process. FDA product code: GEI.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Thermal capsulorrhaphy uses thermal energy to restructure collagen in the capsule or ligaments to reduce the capsule size. This procedure has primarily been evaluated for shoulder joint instability and proposed to treat capsular laxity in other joints.

The literature does not support use of thermal capsulorrhaphy. The few available comparative studies do not support that this procedure is an efficacious treatment for shoulder instability. The case series report a high rate of unsatisfactory results and complications, raising the potential for a net harm. Because of the lack of efficacy and potential for harm, this procedure is considered not medically necessary.

Supplemental Information
Practice Guidelines and Position Statements
In 2010, the American Academy of Orthopaedic Surgeons published patient information on thermal capsular shrinkage. The information provided stated that thermal capsular shrinkage was developed as a less invasive way to treat a shoulder that is loose and frequently dislocates. Early short-term results were promising and the procedure gained in popularity. However, more recent results over a longer follow-up period have shown a much higher failure rate and more complications than were first reported. As a result, the procedure is used less frequently.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

References
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 4 of 8
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy #  00033
Original Effective Date:  05/12/2003
Current Effective Date:  04/10/2023

15. Lubowitz JH, Poehling GG. Glenohumeral thermal capsulorrhaphy is not recommended--shoulder chondrolysis requires additional research [editorial]. Arthroscopy. Jul 2007;23(7):687. PMID 17637401

Policy History
Original Effective Date:  05/12/2003
Current Effective Date:  04/10/2023
04/25/2003  Medical Policy Committee review
05/12/2003  Managed Care Advisory Council approval
05/03/2005  Medical Director review
05/17/2005  Medical Policy Committee review. Format revision. Rationale/ source added. Policy statement expanded from; “electrothermal arthroscopy is investigational” to, “as a treatment of joint instability, including, but not limited to the shoulder, knee and elbow”
05/23/2005  Managed Care Advisory Council approval
07/07/2006  Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
04/04/2007  Medical Director review
04/18/2007  Medical Policy Committee approval. Name changed from Electrothermal Arthroscopy to Thermal Capsulorrhaphy as a Treatment of Joint Instability. No change to coverage eligibility.
03/04/2009  Medical Director review
03/18/2009  Medical Policy Committee approval. No change to coverage eligibility.
03/05/2010  Medical Director review
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

03/19/2010 Medical Policy Committee approval. No change to coverage eligibility.
03/03/2011 Medical Policy Committee review
03/16/2011 Medical Policy Implementation Committee approval. Coverage changed from investigational to not medically necessary.
03/01/2012 Medical Policy Committee review
03/21/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/07/2013 Medical Policy Committee review
03/20/2013 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/06/2014 Medical Policy Committee review
03/19/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2015 Medical Policy Committee review
03/20/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
03/03/2016 Medical Policy Committee review
03/16/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
03/02/2017 Medical Policy Committee review
03/15/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/01/2018 Medical Policy Committee review
03/21/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/07/2019 Medical Policy Committee review
03/20/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2020 Medical Policy Committee review
03/11/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 6 of 8
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

03/04/2021 Medical Policy Committee review
03/10/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/03/2022 Medical Policy Committee review
03/09/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/02/2023 Medical Policy Committee review
03/08/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date: 03/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Thermal Capsulorrhaphy as a Treatment of Joint Instability

Policy # 00033
Original Effective Date: 05/12/2003
Current Effective Date: 04/10/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>29999</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2300</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.